Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Revolution Medicines Inc. (RVMD:NASDAQ), powered by AI.
Revolution Medicines Inc. is currently trading at $147.01. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Revolution Medicines Inc. on Alpha Lenz.
Revolution Medicines Inc.'s P/E ratio is -41.1.
“Revolution Medicines Inc. trades at a P/E of -41.1 (undervalued) with modest ROE of -29.3%.”
Ask for details →Revolution Medicines Inc. is a biotechnology company primarily focused on the development of targeted therapies for cancer treatment. The company aims to create innovative drugs by leveraging the potential of inhibitors that target specific oncogenic pathways. Revolution Medicines Inc. specializes in synthetic lethal technologies and non-covalent inhibitors to address complex molecular targets found in cancer cells. With a strong emphasis on research and development, it collaborates with academic institutions and partners within the biopharmaceutical industry to advance its pipeline of drug candidates. Revolution Medicines Inc. is significantly involved in the oncology sector, with potential impacts on patient care through its commitment to developing precision medicines. As a key player in the biotech landscape, the company contributes to the ongoing evolution of cancer treatment methodologies, seeking to extend and improve patients' lives through state-of-the-art therapeutic options.
“Revolution Medicines Inc. trades at a P/E of -41.1 (undervalued) with modest ROE of -29.3%.”
Ask for details →Revolution Medicines Inc. (ticker: RVMD) is a company listed on NASDAQ in the Healthcare sector (Biotechnology). It has approximately 700 employees. Market cap is $24.7B.
The current price is $147.01 with a P/E ratio of -41.09x and P/B of 10.89x.
ROE is -29.33%.